These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 39008024)

  • 21. Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir.
    Vannappagari V; Thorne C;
    J Acquir Immune Defic Syndr; 2019 Aug; 81(4):371-378. PubMed ID: 30939532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry.
    Ephross SA; Sinclair SM
    Headache; 2014; 54(7):1158-72. PubMed ID: 24805878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exposure to golimumab during pregnancy: Results from the Company's global safety database.
    Otero-Lobato M; Adeyemo A; Higley M; Lomax KG; Geldhof A; Esslinger S
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1240. PubMed ID: 38970433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin.
    Pollack PS; Shields KE; Burnett DM; Osborne MJ; Cunningham ML; Stepanavage ME
    Birth Defects Res A Clin Mol Teratol; 2005 Nov; 73(11):888-96. PubMed ID: 16163683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis.
    Mahadevan U; Dubinsky MC; Su C; Lawendy N; Jones TV; Marren A; Zhang H; Graham D; Clowse MEB; Feldman SR; Baumgart DC
    Inflamm Bowel Dis; 2018 Nov; 24(12):2494-2500. PubMed ID: 29982686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients.
    Ponce-Bobadilla AV; Stodtmann S; Eckert D; Zhou W; Liu W; Mohamed MF
    Clin Pharmacokinet; 2023 Jan; 62(1):101-112. PubMed ID: 36571701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pregnancy in acromegaly patients treated with pegvisomant.
    van der Lely AJ; Gomez R; Heissler JF; Åkerblad AC; Jönsson P; Camacho-Hübner C; Kołtowska-Häggström M
    Endocrine; 2015 Aug; 49(3):769-73. PubMed ID: 25542184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis.
    Law CCY; Kayal M; Mehandru S; Colombel JF
    Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):109-117. PubMed ID: 36681073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pregnancy and fetal outcomes following paternal exposure to glatiramer acetate.
    Kaplan S; Dragut CF; Ghimpeteanu A
    Curr Med Res Opin; 2024 May; 40(5):821-825. PubMed ID: 38577712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of upadacitinib for the treatment of axial spondyloarthritis.
    George N; Liew JW; Dubreuil M
    Immunotherapy; 2023 Oct; 15(15):1227-1237. PubMed ID: 37675498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of upadacitinib in the treatment of psoriatic arthritis.
    Ross Y; Magrey M
    Immunotherapy; 2021 Dec; 13(18):1549-1554. PubMed ID: 34645316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease.
    Mahadevan U; Vermeire S; Lasch K; Abhyankar B; Bhayat F; Blake A; Dubinsky M
    Aliment Pharmacol Ther; 2017 Apr; 45(7):941-950. PubMed ID: 28169436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pregnancy outcomes following exposure to abatacept during pregnancy.
    Kumar M; Ray L; Vemuri S; Simon TA
    Semin Arthritis Rheum; 2015 Dec; 45(3):351-6. PubMed ID: 26210783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.
    Simpson EL; Papp KA; Blauvelt A; Chu CY; Hong HC; Katoh N; Calimlim BM; Thyssen JP; Chiou AS; Bissonnette R; Stein Gold LF; Wegzyn C; Hu X; Liu M; Liu J; Tenorio AR; Chu AD; Guttman-Yassky E
    JAMA Dermatol; 2022 Apr; 158(4):404-413. PubMed ID: 35262646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.
    Karlsson G; Francis G; Koren G; Heining P; Zhang X; Cohen JA; Kappos L; Collins W
    Neurology; 2014 Feb; 82(8):674-80. PubMed ID: 24463630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of upadacitinib in rheumatoid arthritis.
    Tanaka Y
    Mod Rheumatol; 2020 Sep; 30(5):779-787. PubMed ID: 32530345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pregnancy, Fetal, and Infant Outcomes Following Maternal Exposure to Glatiramer Acetate During Pregnancy and Breastfeeding.
    Kaplan S; Zeygarnik M; Stern T
    Drug Saf; 2022 Apr; 45(4):345-357. PubMed ID: 35297004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study.
    Hagino T; Saeki H; Fujimoto E; Kanda N
    J Dermatolog Treat; 2024 Dec; 35(1):2344591. PubMed ID: 38653561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme.
    Raine T; Ishiguro Y; Rubin DT; Finney-Hayward T; Vladea R; Liu J; Phillips C; Cheng E; Targownik L; Loftus EV
    J Crohns Colitis; 2024 May; 18(5):695-707. PubMed ID: 37942921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.